Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02701257 · ClinicalTrials.gov registry record · NA
The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02701257: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT02701257 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02701257, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will compare two different models of a wearable bionic pancreas device (the iPhone-based bionic pancreas vs. the iLet bionic pancreas) in adult participant with type 1 diabetes. Both bionic pancreas devices measure glucose levels every five minutes and then give insulin and/or glucagon automatically to regulate the blood glucose (BG).
Interventions
- DRUG Lilly glucagon
- DEVICE iPhone bionic pancreas
- DEVICE iLet bionic pancreas
- DRUG Xeris Xerisol glucagon
- DEVICE iLet infusion set
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02701257
The ClinicalTrials.gov registry entry for NCT02701257 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Lilly glucagon is the first listed.
NCT02701257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02701257 about?
NCT02701257 is a clinical study titled "The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas". This study will compare two different models of a wearable bionic pancreas device (the iPhone-based bionic pancreas vs. the iLet bionic pancreas) in adult participant with type 1 diabetes. Both bionic pancreas devices measure glucose levels every five minutes and then give insulin and/or glucagon au...
What is the current status of trial NCT02701257?
This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2016-03. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02701257?
The interventions under investigation include: Lilly glucagon (DRUG), iPhone bionic pancreas (DEVICE), iLet bionic pancreas (DEVICE), Xeris Xerisol glucagon (DRUG), iLet infusion set (DEVICE).
Who is sponsoring clinical trial NCT02701257?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.